Dr. Pitchai Balakumar
My Social Links

Dr. Pitchai Balakumar

Assistant Professor
Rajendra Institute of Technology and Sciences, India

Highest Degree
Ph.D. in Pharmacology and Toxicology from Rajendra Institute of Technology and Sciences, India

Share this Profile

Area of Interest:

Pharmacology and Toxicology
100%
Cardiac Hypertrophy
62%
Myocardial Ischemia
90%
Myocardial Preconditioning
75%
Vascular Endothelial Physiology
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Balakumar, P., S. Kathuria, G. Taneja, S. Kalra and N. Mahadevan, 2011. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?. J. Mol. Cell. Cardiol., .
    PubMed  |  
  2. Balakumar, P., N. Sharma, S. Kathuria, L. Babbar and N. Mahadevan, 2011. Perspectives in renin-angiotensin-aldosterone system blockade: What's new? Int. J. Recent Adv. Pharm. Res., 1: 1-7.
  3. Balakumar, P., N. Sharma, P. Krishan and N. Mahadevan, 2011. Linagliptin: A newly approved dipeptidyl peptidase-4 inhibitor for the management of type-2 diabetes mellitus. Int. J. Recent Adv. Pharm. Res., 3: 11-14.
  4. Balakumar, P. and N.K. Sharma, 2011. Healing the diabetic heart: Does myocardial preconditioning work?. Cell. Signall., 10.1016/j.cellsig.2011.09.007.
    CrossRef  |  
  5. Balakumar, P. and N. Mahadevan, 2011. Multifaceted cardiac signal transduction mediated by G protein-coupled receptors: Potential target sites where an unambiguous attention is needed for exploring new drugs for cardiovascular disorders. Biomed. Aging Pathol., 10.1016/j.biomag.2011.04.004.
    CrossRef  |  
  6. Balakumar, P. and N. Mahadevan, 2011. Interplay between statins and PPARs in improving cardiovascular outcomes: A double-edged sword?. Br. J. Pharmacol., 10.1111/j.1476-5381.2011.01597.x.
    CrossRef  |  
  7. Balakumar, P. and N. Mahadevan, 2011. Azilsartan: A novel angiotensin-II type 1 receptor blocker for treating hypertension. Int. J. Recent Adv. Pharm. Res., 2: 11-13.
  8. Balakumar, P. and G. Jagadeesh, 2011. Potential cross-talk between (pro)renin receptors and Wnt/frizzled receptors in cardiovascular and renal disorders. Hypertension Res., 10.1038/hr.2011.113.
    CrossRef  |  PubMed  |  
  9. Balakumar, P, A. Rohilla and N. Mahadevan, 2011. Pleiotropic actions of fenofibrate on the heart. Pharmacol. Res., 63: 8-12.
    PubMed  |  
  10. Verma, S., K. Reddy and P. Balakumar, 2010. The defensive effect of benfotiamine in sodium arsenite-induced experimental vascular endothelial dysfunction. Biol. Trace Element Res., 137: 96-109.
    CrossRef  |  
  11. Rohilla, A., G. Singh, M. Singh and P. Balakumar, 2010. Possible involvement of PKC-delta in the abrogated cardioprotective potential of ischemic preconditioning in hyperhomocysteinemic rat hearts. Biomed. Pharmacother., 64: 195-202.
    CrossRef  |  
  12. Kaur, T., R.K. Goel and P. Balakumar, 2010. Effect of rosiglitazone in sodium arseniteinduced experimental vascular endothelial dysfunction. Arch. Pharm. Res., 33: 611-618.
    CrossRef  |  
  13. Kaur, J., K. Reddy and P. Balakumar, 2010. The novel role of fenofibrate in preventing nicotine and sodium arsenite-induced vascular endothelial dysfunction in the rat. Cardiovascular Toxicol., 10: 227-238.
    PubMed  |  
  14. Balakumar, P., A. Rohilla, P. Krishan, P. Solairaj and A. Thangathirupathi, 2010. The multifaceted therapeutic potential of benfotiamine. Pharmacol. Res., 61: 482-488.
    PubMed  |  
  15. Balakumar, P., A. Rohilla and A. Thangathirupathi, 2010. Gentamicin-induced nephrotoxicity: Do we have a promising therapeutic approach to blunt it? Pharmacol. Res., 62: 179-186.
    PubMed  |  Direct Link  |  
  16. Balakumar, P. and G. Jagadeesh, 2010. Multifarious molecular signaling cascades of cardiac hypertrophy: Can the muddy waters be cleared?. Pharmacol. Res., 62: 365-383.
    PubMed  |  
  17. Balakumar, P. and G. Jagadeesh, 2010. Cardiovascular and renal pathological implications of prorenin, renin and the (pro)renin receptor: Promising young players from the Old renin-angiotensin-aldosterone system. J. Cardiovascular Pharmacol., 56: 570-579.
  18. Arora, M.K., K. Reddy and P. Balakumar, 2010. The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy. Eur. J. Pharmacol., 636: 137-144.
    CrossRef  |  PubMed  |  Direct Link  |  
  19. Singh, G., A. Rohilla, M. Singh and P. Balakumar, 2009. Possible role of JAK-2 in attenuated cardioprotective effect of ischemic preconditioning in hyperhomocysteinemic rat hearts. Yakugaku Zasshi, 129: 523-535.
    CrossRef  |  PubMed  |  
  20. Rohilla, A. and P. Balakumar, 2009. The infarct size-limiting effect of ischemic postconditioning (IPOC) is suppressed in isolated hyperhomocyteinemic rat hearts: The possible role of PKC-delta. Biomed. Pharmacother., 63: 787-791.
    PubMed  |  
  21. Balakumar, P., V.A. Chakkarwar, P. Krishan and M. Singh, 2009. Vascular endothelial dysfunction: A tug of war in diabetic nephropathy? Biomed. Pharmacother., 63: 171-179.
    PubMed  |  
  22. Balakumar, P., V.A. Chakkarwar and M. Singh, 2009. Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Mol. Cell. Bioch., 320: 149-162.
    CrossRef  |  
  23. Balakumar, P., R. Sharma, A.N. Kalia and M. Singh, 2009. Hyperuricemia: Is it a risk factor for vascular endothelial dysfunction and associated cardiovascular disorders? Curr. Hypertens. Rev., 5: 1-6.
    Direct Link  |  
  24. Balakumar, P., M.K. Arora, J. Reddy and M.B. Anand-Srivastava, 2009. Pathogenesis of diabetic nephropathy: Involvement of multifaceted signalling mechanism. J. Cardiovasc. Pharmacol., 54: 129-138.
  25. Balakumar, P., M.K. Arora and M. Singh, 2009. Emerging role of PPAR ligands in the management of diabetic nephropathy. Pharmacol. Res., 60: 170-173.
    CrossRef  |  
  26. Balakumar, P., J. Reddy and M. Singh, 2009. Do resident renal mast cells play a role in the pathogenesis of diabetic nephropathy? Mol. Cell. Biochem., 330: 187-192.
    CrossRef  |  
  27. Balakumar, P., H. Singh, M. Singh and M.B. Anand-Srivastava, 2009. The impairment of preconditioning-mediated cardioprotection in pathological conditions. Pharmacol. Res., 60: 18-23.
    PubMed  |  
  28. Balakumar, P., H. Singh and M.B. Anand-Srivastava, 2009. Adenosine-A1 receptors activation restores the suppressed cardioprotective effects of ischemic preconditioning in hyperhomocysteinemic rat hearts. J. Cardiovasc. Pharmacol., 54: 204-212.
    PubMed  |  
  29. Balakumar, P., A. Rohilla, G. Singh, K. Singh and M. Singh, 2009. Modulation of cardioprotective effect of ischemic pre-and postconditioning in the hyperhomocysteinemic rat heart. Meth. Find. Exp. Clin. Pharmacol., 31: 71-79.
  30. Balakumar, P. and J. Kaur, 2009. Is nicotine a key player or spectator in the induction and progression of cardiovascular disorders? Pharmacol. Res., 60: 361-368.
    PubMed  |  
  31. Balakumar, P. and J. Kaur, 2009. Arsenic exposure and cardiovascular disorders: An overview. Cardiovasc. Toxicol., 9: 169-176.
    CrossRef  |  
  32. Balakumar, P, M.K. Arora, S.S. Ganti, J. Reddy and M. Singh, 2009. Recent advances inpharmacotherapy for diabetic nephropathy: Current perspectives and future directions. Pharmacol. Res., 60: 24-32.
    PubMed  |  
  33. Singh, A.P., M. Singh and P. Balakumar, 2008. Effect of mast cell stabilizers in hyperhomocysteinemia-induced cardiac hypertrophy in rats. J. Cardiovascular Pharmacol., 51: 596-604.
    PubMed  |  
  34. Kumar, V., S. Mukhopadhyay, P.S. Bedi, G. Singh and P. Balakumar, 2008. A novel modulatory role of vitamin D3 in exercise-induced apoptosis of rat skeletal muscle. Am. J. Food Technol., 3: 361-372.
    CrossRef  |  Direct Link  |  
  35. Kalia, A.N., N. Mahadevan and P. Balakumar, 2008. Current trends in phytomedicine and challenges ahead. Indian J. Nat. Prod., 24: 38-40.
  36. Jindal, S., M. Singh and P. Balakumar, 2008. Effect of bis (maltolato) oxovanadium (BMOV) in uric acid and sodium arsenite-induced vascular endothelial dysfunction in rats. Int. J. Cardiol., 128: 383-391.
  37. Balakumar, P., V.A. Chakkarwar, V. Kumar, A. Jain, J. Reddy and M. Singh, 2008. Experimental models for nephropathy. J. Renin Angiotensin Aldosterone Syst., 9: 189-195.
    CrossRef  |  PubMed  |  Direct Link  |  
  38. Balakumar, P., T. Kaur and M. Singh, 2008. Potential target sites to modulate vascular endothelial dysfunction: Current perspectives and future directions. Toxicology, 245: 49-64.
    PubMed  |  
  39. Balakumar, P., R.U. Koladiya, S. Ramasamy, A. Rathinavel and M. Singh, 2008. Pharmacological interventions to prevent vascular endothelial dysfunction: Future directions. J. Health Sci., 54: 1-16.
    Direct Link  |  
  40. Balakumar, P., R. Sharma and M. Singh, 2008. Benfotiamine attenuates nicotine and uric acid-induced vascular endothelial dysfunction in the rat. Pharmacol. Res., 58: 356-363.
    PubMed  |  
  41. Balakumar, P., B. Pateliya, G. Singh and M Singh, 2008. Pathophysiology of ischemia/reperfusion-induced myocardial injury: What we have learned from preconditioning and postconditioning? Iran. J. Pharmacol. Ther., 7: 115-122.
    Direct Link  |  
  42. Balakumar, P., A.P. Singh, S.S. Ganti, P. Krishan, S. Ramasamy and M. Singh, 2008. Resident cardiac mast cells: Are they the major culprit in the pathogenesis of cardiac hypertrophy?. Basic Clin. Pharmacol. Toxicol., 102: 5-9.
    Direct Link  |  
  43. Balakumar, P., A. Rohilla and M. Singh, 2008. Preconditioning and postconditioning to limit ischemia-reperfusion-induced myocardial injury: What could be the next footstep? Pharmacol. Res., 57: 403-412.
  44. Rose, M., P. Balakumar and M. Singh, 2007. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in Rats. Pharmacol., 80: 177-184.
  45. Rathinavel, A., G.S. Selvam, K. Ananthamurthy, M. Singh, P. Balakumar, S. Ramasamy and T. Ramprasath, 2007. Functional characterization of cardiac isoform of alpha 2 macroglobulin (CA2M): Identification of non-hypertrophic domain. Cardiology, 3: 20-23.
    CrossRef  |  Direct Link  |  
  46. Balakumar, P., S. Murthy and G. Jagadeesh, 2007. The basic concepts of scientific research and communication. Indian J. Pharmacol., 39: 303-306.
  47. Balakumar, P., S. Jindal, D.I. Shah and M. Singh, 2007. Experimental models for vascular endothelial dysfunction. Trends Med. Res., 2: 12-20.
    CrossRef  |  Direct Link  |  
  48. Balakumar, P., S. Jindal and M. Singh, 2007. Novel use of uric acid and sodium arsenite to induce vascular endothelial dysfunction in rats. J. Pharmacol. Toxicol., 2: 437-446.
    CrossRef  |  Direct Link  |  
  49. Balakumar, P., M. Rose, S.S. Ganti, P. Krishan and M. Singh, 2007. PPAR dual agonists: Are they opening pandora's box?. Pharmacol. Res., 56: 91-98.
    CrossRef  |  
  50. Balakumar, P., M. Rose and M. Singh, 2007. Peroxisome proliferator activated receptor agonists: Emerging therapy for cardiovascular complications. J. Pharmacol. Toxicol., 2: 205-219.
    CrossRef  |  Direct Link  |  
  51. Balakumar, P., M. Rose and M. Singh, 2007. PPAR ligands. Are they potential agents for cardiovascular disorders. Pharmacology, 80: 1-10.
    CrossRef  |  
  52. Balakumar, P., M. Rose and M. Singh, 2007. Effect of fenofibrate in pressure overload-induced experimental cardiac hypertrophy. Int. J. Biol. Chem., 1: 104-110.
    CrossRef  |  Direct Link  |  
  53. Balakumar, P., A.P. Singh, S.S. Ganti and M. Singh, 2007. Hyperhomocysteinemia and cardiovascular disorders: Is there a correlation? Trends Med. Res., 2: 160-166.
    CrossRef  |  Direct Link  |  
  54. Balakumar, P., A.P. Singh and M. Singh, 2007. Appraisal of state-of-the-art rodent models of heart failure. J. Pharmacol. Toxicol. Meth., 56: 1-10.
    CrossRef  |  
  55. Balakumar, P. and S. Manjeet, 2006. Effect of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase in experimental cardiac hypertrophy. Int. J. Pharmacol., 2: 543-548.
    CrossRef  |  Direct Link  |  
  56. Balakumar, P. and M. Singh, 2006. Possible role of poly (ADP-ribose) polymerase in pathological and physiological cardiac hypertrophy. Meth. Find. Exp. Clin. Pharmacol., 28: 683-689.
    Direct Link  |  
  57. Balakumar, P. and M. Singh, 2006. Possible role of caspase-3 in pathological and physiological cardiac hypertrophy in rats. Basic Clin. Pharmacol. Toxicol., 99: 418-424.
    CrossRef  |  Direct Link  |  
  58. Balakumar, P. and M. Singh, 2006. Emerging drug therapies for heart failure. Iranian J. Pharmacol. Therap., 5: 87-94.
    Direct Link  |  
  59. Balakumar, P. and M. Singh, 2006. Differential role of rho-kinase in pathological and physiological cardiac hypertrophy in rats. Pharmacology, 78: 91-97.
    Direct Link  |  
  60. Balakumar, P. and M. Singh, 2006. Anti-TNF-α therapy in heart failure: Future directions. Basic Clin. Pharmacol. Toxicol., 99: 391-397.
  61. Bali, A., Y. Bansal, M. Sugumaran, J.S. Saggu and P. Balakumar et al., 2005. Design, synthesis, and evaluation of novelly substituted benzimidazole 14 compounds as angiotensin II receptor antagonists. Bioorg. Med. Chem. Lett., 15: 3962-3965.
    CrossRef  |  Direct Link  |  
  62. Balakumar, P. and M. Singh, 2005. The possible role of TNF-α in physiological and pathophysiological cardiac hypertrophy in rats. Ira. J. Pharmacol. Ther., 4: 138-142.
  63. Asockson, C., V. Ganesan, L. Anuradha, N.P. Ashokkumar, P. Balakumar and V.G. Geetha, 2001. Hepatoprotective activity of punica granatum. Indian Drugs, 38: 183-186.